{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:20:30Z","timestamp":1788380430951,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA009531"],"award-info":[{"award-number":["CA009531"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA022453"],"award-info":[{"award-number":["P30 CA022453"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021707","name":"New Brunswick Children's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006710","name":"Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007284","name":"School of Medicine, Wayne State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017302","name":"Barbara Ann Karmanos Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018369","name":"RE Children\u2019s Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bcp.2022.115283","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T11:03:38Z","timestamp":1664967818000},"page":"115283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia"],"prefix":"10.1016","volume":"205","author":[{"given":"Katie","family":"Hege Hurrish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasini A.","family":"Kalpage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"H\u00fcttemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Dombkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0005","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2022.115283_b0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2022.115283_b0015","unstructured":"(SEER) NCI. Cancer stat facts: leukemia - acute myeloid leukemia 2020 [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11899-019-00535-7","article-title":"Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions","volume":"14","author":"DiNardo","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bcp.2022.115283_b0025","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.2147\/CMAR.S180724","article-title":"Evaluating venetoclax and its potential in treatment-naive acute myeloid leukemia","volume":"11","author":"Knight","year":"2019","journal-title":"Cancer Manage. Res."},{"issue":"17","key":"10.1016\/j.bcp.2022.115283_b0030","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115283_b0035","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica."},{"key":"10.1016\/j.bcp.2022.115283_b0040","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","volume":"12","author":"Aldoss","year":"2021","journal-title":"Ther. Adv. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115283_b0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11523-020-00711-3","article-title":"Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond","volume":"15","author":"Choi","year":"2020","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bcp.2022.115283_b0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bcp.2019.01.015","article-title":"A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics","volume":"162","author":"Knight","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0055","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2022.115283_b0060","doi-asserted-by":"crossref","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"issue":"9","key":"10.1016\/j.bcp.2022.115283_b0065","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/cancers12092400","article-title":"Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation","volume":"12","author":"Liu","year":"2020","journal-title":"Cancers. (Basel)"},{"issue":"11","key":"10.1016\/j.bcp.2022.115283_b0070","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3324\/haematol.2018.201343","article-title":"Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia","volume":"104","author":"Li","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0075","first-page":"1262","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","volume":"106","author":"Li","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0080","doi-asserted-by":"crossref","first-page":"e37699","DOI":"10.1371\/journal.pone.0037699","article-title":"Mitochondrial structure, function and dynamics are temporally controlled by c-Myc","volume":"7","author":"Graves","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bcp.2022.115283_b0085","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood.2021013201","article-title":"The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation","volume":"139","author":"Amaya","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2022.115283_b0090","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115283_b0095","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.bcp.2022.115283_b0100","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0105","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2022.115283_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.bcp.2022.115283_b0115","doi-asserted-by":"crossref","first-page":"e79106","DOI":"10.1371\/journal.pone.0079106","article-title":"Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51","volume":"8","author":"Xie","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2022.115283_b0120","doi-asserted-by":"crossref","unstructured":"S. Liu, X. Qiao, S. Wu, Y. Gai, Y. Su, H. Edwards, et al. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis. 2022; Online ahead of print.","DOI":"10.1007\/s10495-022-01756-7"},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0125","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcph.1275","article-title":"Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients","volume":"59","author":"Bao","year":"2019","journal-title":"J. Clin. Pharmacol."},{"issue":"43","key":"10.1016\/j.bcp.2022.115283_b0130","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0135","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/cptx.76","article-title":"Acute Metabolic Switch Assay Using Glucose\/Galactose Medium in HepaRG Cells to Detect Mitochondrial Toxicity","volume":"80","author":"Kamalian","year":"2019","journal-title":"Curr. Protoc. Toxicol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115283_b0140","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/gb-2003-4-10-r69","article-title":"An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets","volume":"4","author":"Zeller","year":"2003","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115283_b0145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","article-title":"The emerging role and targetability of the TCA cycle in cancer metabolism","volume":"9","author":"Anderson","year":"2018","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0150","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Martinez-Reyes","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2022.115283_b0155","first-page":"1436","article-title":"Targeting 2-oxoglutarate dehydrogenase for cancer treatment","volume":"12","author":"Chang","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0160","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.bcp.2022.115283_b0165","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2014-08-594408","article-title":"AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress","volume":"125","author":"Sriskanthadevan","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2022.115283_b0170","doi-asserted-by":"crossref","first-page":"e0134049","DOI":"10.1371\/journal.pone.0134049","article-title":"c-Myc and AMPK Control Cellular Energy Levels by Cooperatively Regulating Mitochondrial Structure and Function","volume":"10","author":"Edmunds","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0175","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1007\/s13277-015-4479-7","article-title":"Nutrient deprivation-related OXPHOS\/glycolysis interconversion via HIF-1alpha\/C-MYC pathway in U251 cells","volume":"37","author":"Liu","year":"2016","journal-title":"Tumour Biol."},{"issue":"7239","key":"10.1016\/j.bcp.2022.115283_b0180","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature07823","article-title":"c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism","volume":"458","author":"Gao","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2022.115283_b0185","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0190","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bcp.2022.115283_b0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.bcp.2022.115283_b0200","doi-asserted-by":"crossref","first-page":"106194","DOI":"10.1016\/j.leukres.2019.106194","article-title":"Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)","volume":"84","author":"Yun","year":"2019","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115283_b0205","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.stem.2010.07.011","article-title":"The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche","volume":"7","author":"Simsek","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.bcp.2022.115283_b0210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","article-title":"Acute myeloid leukaemia in the elderly: a review","volume":"152","author":"Pollyea","year":"2011","journal-title":"Br. J. Haematol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522200377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522200377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:13:24Z","timestamp":1762096404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522200377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"alternative-id":["S000629522200377X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115283","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115283"}}